Loading viewer...
conference
Format: PDF conference
Phase 2 clinical trial results for mRNA-4157 (V940), an individualized neoantigen therapy developed by Moderna and Merck for high-risk stage III/IV melanoma. The study evaluates distant metastasis-free survival in patients receiving adjuvant immune checkpoint inhibitor therapy combined with the investigational mRNA vaccine.
conference
25 Pages
conference
31 Pages
Unknown
Newfield Exploration 2016 Capital One Energy Conference
conferenceconference
18 Pages
Newfield Exploration Company
First Capital Realty Q3 2016 Conference Call
conferenceconference
29 Pages
First Capital Realty